| Literature DB >> 27567557 |
Qin Qin1, Dan Luo1, Yunjie Shi1, Qingqing Zhao1, Yuan Chen1, Jing Wu1, Min Zhao2.
Abstract
Corneal graft rejection is the major reason for transplant failure. CD25 plays an important role in the induction of corneal graft rejection by regulating CD4(+) T cell function. Furthermore, CD25-mediated signaling is closely associated with the expression of Treg cytokines (IL-10, TGF-β) and Th1 cytokines (IFN-γ, IL-1β, and TNF-α). In the current study, corneal transplantation was performed on Wistar rats as donors and Sprague-Dawley rats as recipients. The survival curves indicated that CD25 siRNA treatment significantly prolonged graft survival time (mean survival time [MST], 14.8 ± 0.7 days) as compared with controls (MST, 7.6 ± 0.7 days; n = 12, p < 0.01). HE staining showed that CD25 siRNA alleviated inflammatory cell infiltration. At days 3, 7, 14, and 21, the mRNA and protein expression of CD25 in the CD25 siRNA groups were less than those of the control group, although the most significant decrease of CD25 protein was at day 3. The expression of IL-10 and TGF-β in the CD25 siRNA group increased, while IFN-γ, IL-1β, and TNF-α expression decreased, as well as no significant changes in Foxp3 expression were observed at day 14 post-operation. In conclusion, CD25 siRNA gene therapy played a protective role in corneal graft rejection via up-regulation of Treg cytokine expression and down-regulation of Th1 cytokine expression.Entities:
Keywords: CD25; CD25 siRNA treatment; Th1 cytokines; Treg cytokines
Mesh:
Substances:
Year: 2016 PMID: 27567557 DOI: 10.1016/j.exer.2016.08.010
Source DB: PubMed Journal: Exp Eye Res ISSN: 0014-4835 Impact factor: 3.467